Press Release **For Immediate Release**

Glenmark Generics receives ANDA approval for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.09 mg/0.02 mg

Mumbai, India, April 10, 2015 – Glenmark Generics Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for the oral contraceptive, Levonorgestrel/Ethinyl Estradiol Tablets USP, 0.09 mg/0.02 mg, the therapeutic equivalent of Lybrel® of Wyeth Pharmaceuticals, Inc. (which is no longer being marketed in the United States).

Lybrel® is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. According to IMS Health sales data for the 12 month period ending February 2015, the Lybrel® market achieved annual sales of approximately $6.4 million*.

WARNING: Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.

Today's approval marks Glenmark's 11th oral contraceptive authorized for distribution by the U.S. FDA. Glenmark plans to commence shipping of Levonorgestrel/Ethinyl Estradiol Tablets, 0.09 mg/0.02 mg immediately.

Glenmark's current portfolio consists of 97 products authorized for distribution in the U.S. marketplace and 68 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Lybrel® is a registered trademark of Wyeth LLC.

*IMS Health National Sales Perspectives: Retail & Non-Retail, February 2015

About Glenmark Generics Limited

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and developing an EU presence. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 80 countries, including the US, various countries in the EU, South America and India.

Note: "The Hon'ble Bombay High Court passed an order approving the amalgamation of Glenmark Generics Limited with Glenmark Pharmaceuticals Ltd. We are currently in the process of complying with further directions of the said order."

For further information, please contact:

Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919/984
Email: corpcomm@glenmarkpharma.com